Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Organovo Holdings's share price for the quarter that ended in Dec. 2023 was €0.981. Organovo Holdings's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 9.84 Mil. Therefore, Organovo Holdings's market cap for the quarter that ended in Dec. 2023 was €9.65 Mil.
Organovo Holdings's quarterly market cap
declined
from Jun. 2023 (€12.92 Mil) to Sep. 2023 (€10.83 Mil) and
declined
from Sep. 2023 (€10.83 Mil) to Dec. 2023 (€9.65 Mil).
Organovo Holdings's annual market cap
declined
from Mar. 2021 (€70.23 Mil) to Mar. 2022 (€29.44 Mil) and
declined
from Mar. 2022 (€29.44 Mil) to Mar. 2023 (€18.02 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Organovo Holdings's Enterprise Value for Today is €9.42 Mil.
Organovo Holdings Market Cap Historical Data
The historical data trend for Organovo Holdings's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Organovo Holdings's Market Cap
For the Biotechnology subindustry, Organovo Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organovo Holdings's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Organovo Holdings's Market Cap distribution charts can be found below:
* The bar in red indicates where Organovo Holdings's Market Cap falls into.
Organovo Holdings Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Organovo Holdings's Market Cap for the fiscal year that ended in Mar. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organovo Holdings (FRA:4OR1) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Organovo Holdings Market Cap Related Terms
Thank you for viewing the detailed overview of Organovo Holdings's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Organovo Holdings Inc is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications. It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company collaborates with pharmaceutical and academic partners to develop human biological disease models in three dimensions. Organovo's key instrument platform is the NovoGen Bioprinter. The firm's 3-D bioprinting technologies create tissues using living cells and biocompatible hydrogels.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:4OR1 has been successfully added to your 